560 related articles for article (PubMed ID: 11923541)
1. Molecular determinants for the tissue specificity of SERMs.
Shang Y; Brown M
Science; 2002 Mar; 295(5564):2465-8. PubMed ID: 11923541
[TBL] [Abstract][Full Text] [Related]
2. Biomedicine. Defining the "S" in SERMs.
Katzenellenbogen BS; Katzenellenbogen JA
Science; 2002 Mar; 295(5564):2380-1. PubMed ID: 11923515
[No Abstract] [Full Text] [Related]
3. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Pole JC; Gold LI; Orton T; Huby R; Carmichael PL
Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
[TBL] [Abstract][Full Text] [Related]
5. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
8. Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines.
Sasaki H; Hayakawa J; Terai Y; Kanemura M; Tanabe-Kimura A; Kamegai H; Seino-Noda H; Ezoe S; Matsumura I; Kanakura Y; Sakata M; Tasaka K; Ohmichi M
Oncogene; 2008 Apr; 27(19):2737-45. PubMed ID: 18193094
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
Bläuer M; Heinonen PK; Rovio P; Ylikomi T
Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
11. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
12. Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells.
Flamini MI; Sanchez AM; Goglia L; Tosi V; Genazzani AR; Simoncini T
Mol Hum Reprod; 2009 Oct; 15(10):675-85. PubMed ID: 19541800
[TBL] [Abstract][Full Text] [Related]
13. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
14. Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene.
Levy N; Zhao X; Tang H; Jaffe RB; Speed TP; Leitman DC
Endocrinology; 2007 Jul; 148(7):3449-58. PubMed ID: 17395694
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre M; Smith CL
J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
18. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
19. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
Macaluso M; Cinti C; Russo G; Russo A; Giordano A
Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
[TBL] [Abstract][Full Text] [Related]
20. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
Gao ZO; Gao ZP; Fields JZ; Boman BM
Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
